Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)
Others
Ratios

Benitec Biopharma (BNTC) Profit After Tax (2019 - 2025)

Benitec Biopharma's Profit After Tax history spans 7 years, with the latest figure at $5.1 million for Q1 2025.

  • For Q1 2025, Profit After Tax rose 218.21% year-over-year to $5.1 million; the TTM value through Mar 2025 reached -$14.3 million, down 566.28%, while the annual FY2024 figure was -$21.8 million, 111340.55% down from the prior year.
  • Profit After Tax for Q1 2025 was $5.1 million at Benitec Biopharma, up from -$9.6 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $14.9 million in Q2 2023 and bottomed at -$9.6 million in Q4 2024.
  • The 5-year median for Profit After Tax is -$4.8 million (2021), against an average of -$3.4 million.
  • The largest annual shift saw Profit After Tax soared 391.79% in 2023 before it tumbled 132.05% in 2024.
  • A 5-year view of Profit After Tax shows it stood at -$4.8 million in 2021, then fell by 12.24% to -$5.4 million in 2022, then decreased by 25.63% to -$6.8 million in 2023, then plummeted by 40.51% to -$9.6 million in 2024, then skyrocketed by 152.95% to $5.1 million in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Profit After Tax are $5.1 million (Q1 2025), -$9.6 million (Q4 2024), and -$5.1 million (Q3 2024).